SAFETYLIT WEEKLY UPDATE

We compile citations and summaries of about 400 new articles every week.
RSS Feed

HELP: Tutorials | FAQ
CONTACT US: Contact info

Search Results

Journal Article

Citation

Holtmann M, Bolte S, Poustka F. Nervenarzt, Der 2005; 77(11): 1332-1337.

Vernacular Title

Suizidalitat bei depressiven Kindern und Jugendlichen unter Behandlung mit

Affiliation

Klinik für Psychiatrie und Psychotherapie des Kindes- und Jugendalters, Klinikum der Johann-Wolfgang-Goethe-Universität, Frankfurt/Main.

Copyright

(Copyright © 2005, Holtzbrinck Springer Nature Publishing Group)

DOI

10.1007/s00115-005-1952-3

PMID

15986258

Abstract

Due to concerns that selective serotonin reuptake inhibitors (SSRI) might be associated with an increased risk of suicidal ideation and suicide attempts in depressive children and adolescents, treatment with these drugs is controversial. All available data from randomised controlled trials on SSRIs treating depression in these age groups were examined regarding efficacy and suicidality. Results suggest that fluoxetine and, less clearly, sertraline are effective in such treatment. A meta-analysis yielded no statistically significant difference between treatment with SSRI and placebo with regard to the occurrence of suicidal behavior. Following evidence-based criteria, the risk:benefit ratio is favourable for fluoxetine and sertraline. Their use in the pharmacotherapy of depressive children and adolescents is indicated.

NEW SEARCH


All SafetyLit records are available for automatic download to Zotero & Mendeley
Print